{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=FDC+fianlimab%2Bcemiplimab", "query": { "intervention": "FDC fianlimab+cemiplimab" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 19, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=FDC+fianlimab%2Bcemiplimab&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-27T01:10:36.132Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07223541", "title": "Cemiplimab or Cemiplimab and Fianlimab After Stereotactic Body Radiotherapy in Clear Cell Renal Cell Carcinoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Clear Cell Renal Cell Carcinoma" ], "interventions": [ { "name": "Cemiplimab 350 MG Intravenous Solution", "type": "DRUG" }, { "name": "Fianlimab 1600 MG Intravenous Solution", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Oklahoma", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 72, "start_date": "2026-01-15", "completion_date": "2031-08", "has_results": false, "last_update_posted_date": "2026-03-02", "last_synced_at": "2026-09-27T01:10:36.132Z", "location_count": 1, "location_summary": "Oklahoma City, Oklahoma", "locations": [ { "city": "Oklahoma City", "state": "Oklahoma" } ], "official_url": "https://clinicaltrials.gov/study/NCT07223541" }, { "nct_id": "NCT06918132", "title": "Cemiplimab and Fianlimab Before Surgery for the Treatment of Stage IB-IIIB Non-Small Cell Lung Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lung Non-Small Cell Carcinoma", "Stage IB Lung Cancer AJCC v8", "Stage II Lung Cancer AJCC v8", "Stage IIIA Lung Cancer AJCC v8", "Stage IIIB Lung Cancer AJCC v8" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Cemiplimab", "type": "BIOLOGICAL" }, { "name": "Fianlimab", "type": "BIOLOGICAL" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Surgical Procedure", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2025-04-29", "completion_date": "2027-04-29", "has_results": false, "last_update_posted_date": "2026-02-24", "last_synced_at": "2026-09-27T01:10:36.132Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT06918132" }, { "nct_id": "NCT05352672", "title": "Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "Fianlimab", "type": "DRUG" }, { "name": "Cemiplimab", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 1546, "start_date": "2022-07-14", "completion_date": "2031-09-16", "has_results": false, "last_update_posted_date": "2026-04-22", "last_synced_at": "2026-09-27T01:10:36.132Z", "location_count": 5, "location_summary": "La Jolla, California • Los Angeles, California • Orlando, Florida + 2 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orlando", "state": "Florida" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Knoxville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT05352672" }, { "nct_id": "NCT07650266", "title": "A Study of Cemiplimab and Fianlimab in People With Nasopharyngeal Carcinoma", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Nasopharyngeal Carcinoma", "Nasopharyngeal Cancer", "Nasopharynx Carcinoma", "Nasopharynx Cancer" ], "interventions": [ { "name": "Cemiplimab", "type": "DRUG" }, { "name": "Fianlimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2026-09", "completion_date": "2030-07", "has_results": false, "last_update_posted_date": "2026-08-11", "last_synced_at": "2026-09-27T01:10:36.132Z", "location_count": 7, "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "Harrison", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07650266" }, { "nct_id": "NCT06190951", "title": "A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "cemiplimab", "type": "DRUG" }, { "name": "Fixed Dose Combination (FDC) cemiplimab+fianlimab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 151, "start_date": "2024-09-18", "completion_date": "2030-12-09", "has_results": false, "last_update_posted_date": "2026-02-10", "last_synced_at": "2026-09-27T01:10:36.132Z", "location_count": 28, "location_summary": "La Jolla, California • Los Angeles, California • Newport Beach, California + 22 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06190951" }, { "nct_id": "NCT06205836", "title": "Cemiplimab With or Without Fianlimab to Treat Older Patients With Localized or Locally Advanced MSI-H Colorectal Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colorectal Cancer" ], "interventions": [ { "name": "Cemiplimab", "type": "DRUG" }, { "name": "Fianlimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 44, "start_date": "2024-06-13", "completion_date": "2030-05", "has_results": false, "last_update_posted_date": "2026-05-06", "last_synced_at": "2026-09-27T01:10:36.132Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT06205836" }, { "nct_id": "NCT05608291", "title": "A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "Fianlimab", "type": "DRUG" }, { "name": "Cemiplimab", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 1564, "start_date": "2023-01-16", "completion_date": "2030-04-03", "has_results": false, "last_update_posted_date": "2026-07-06", "last_synced_at": "2026-09-27T01:10:36.132Z", "location_count": 28, "location_summary": "La Jolla, California • San Francisco, California • Santa Monica, California + 21 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Englewood", "state": "Colorado" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05608291" }, { "nct_id": "NCT07179315", "title": "A Study Comparing Two Immunotherapy Options for Human Papillomavirus Positive HPV-Positive Head and Neck Cancer After Treatment", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Head and Neck Cancer" ], "interventions": [ { "name": "cemiplimab+fianlimab", "type": "DRUG" }, { "name": "Cemiplimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 68, "start_date": "2026-06-09", "completion_date": "2029-11-30", "has_results": false, "last_update_posted_date": "2026-07-16", "last_synced_at": "2026-09-27T01:10:36.132Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT07179315" }, { "nct_id": "NCT05800015", "title": "A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "fianlimab", "type": "DRUG" }, { "name": "cemiplimab", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 160, "start_date": "2023-08-08", "completion_date": "2031-12-23", "has_results": false, "last_update_posted_date": "2026-07-15", "last_synced_at": "2026-09-27T01:10:36.132Z", "location_count": 29, "location_summary": "Tucson, Arizona • Yuma, Arizona • Cerritos, California + 24 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Yuma", "state": "Arizona" }, { "city": "Cerritos", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05800015" }, { "nct_id": "NCT06865339", "title": "Thoracic Radiotherapy and Inhibition of PD-1 and LAG-3 for Locally Advanced Non-Small Cell Lung Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "NSCLC", "Locally Advanced" ], "interventions": [ { "name": "Cemiplimab", "type": "DRUG" }, { "name": "Fianlimab", "type": "DRUG" }, { "name": "Radiotherapy", "type": "RADIATION" }, { "name": "Platinum Doublet Chemotherapy (PDC)", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Montefiore Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 76, "start_date": "2025-08-07", "completion_date": "2027-08", "has_results": false, "last_update_posted_date": "2026-04-13", "last_synced_at": "2026-09-27T01:10:36.132Z", "location_count": 1, "location_summary": "The Bronx, New York", "locations": [ { "city": "The Bronx", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06865339" } ] }